News
TipRanks on MSN14h
BioNTech’s Phase II Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment
The study tests BNT327, an investigational drug administered via intravenous infusion, in combination with standard chemotherapy drugs like etoposide, carboplatin, paclitaxel, and topotecan. The goal ...
TipRanks on MSN1d
BioNTech’s BNT327 Trial: A New Hope for Small-cell Lung Cancer?
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback